Esomeprazole + Budesonide

Phase 2/3Completed

1 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Eosinophilic Esophagitis

Conditions

Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD

Trial Timeline

May 1, 2008 → Dec 1, 2010

NCT ID

NCT00728481

About Esomeprazole + Budesonide

Esomeprazole + Budesonide is a phase 2/3 stage product being developed by AstraZeneca for Eosinophilic Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00728481. Target conditions include Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE.

What happened to similar drugs?

6 of 17 similar drugs in Eosinophilic Esophagitis were approved

Approved (6) Terminated (2) Active (9)

🔄Tezepelumab + TezepelumabAstraZenecaPhase 3

✅BenralizumabAstraZenecaApproved

❌Benralizumab + Matching placeboAstraZenecaPhase 3

🔄BenralizumabAstraZenecaPhase 3

🔄Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to BenralizumabAstraZenecaPhase 3

✅Benralizumab Prefilled SyringeAstraZenecaApproved

🔄Benralizumab + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00728481	Phase 2/3	Completed	May 1, 2008	Dec 1, 2010	Eosinophilic Esophagitis

Competing Products

20 competing products in Eosinophilic Esophagitis

See all competitors

Product	Company	Stage	Hype Score
KHK4563 + KHK4563 + KHK4563 + Placebo	Kyowa Kirin	Phase 2	35
benralizumab + benralizumab + Placebo	Kyowa Kirin	Phase 2	35
SHR-1703 + SHR-1703 Placebo	Jiangsu Hengrui Medicine	Phase 2	35
NS-229 + Placebo	Nippon Shinyaku	Phase 2	42
Tezepelumab + Tezepelumab	AstraZeneca	Phase 3	44
Benralizumab	AstraZeneca	Approved	43
Cohort	AstraZeneca	Pre-clinical	26
Benralizumab + Matching placebo	AstraZeneca	Phase 3	32
Benralizumab	AstraZeneca	Phase 3	44
Benralizumab + Mepolizumab + Placebo to Mepolizumab + Placebo to Benralizumab	AstraZeneca	Phase 3	44
Benralizumab Prefilled Syringe	AstraZeneca	Approved	50
benralizumab	AstraZeneca	Pre-clinical	33
Benralizumab + Placebo	AstraZeneca	Phase 3	44
Benralizumab	AstraZeneca	Phase 3	47
Benralizumab + Placebo	AstraZeneca	Phase 3	32
Tezepelumab + Placebo	AstraZeneca	Phase 2	42
Benralizumab + Placebo	AstraZeneca	Phase 2/3	38
inhaled/swallowed budesonide + viscous/swallowed budesonide	AstraZeneca	Pre-clinical	26
Benralizumab + 129 Xenon	AstraZeneca	Pre-clinical	30
Benralizumab + Placebo	AstraZeneca	Phase 3	40